Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2861-2880 of 3,900 trials

Optic Pathway Glioma: CHF6467 Eye Drops

We are studying the safety and effectiveness of a new eye drop treatment for children and young adults with optic pathway gliomas. This trial aims to see if it can improve their vision.

Optic Glioma≤3 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesNeurologyOphthalmology

Functional Dyspepsia: Rikkunshito Study

We are investigating whether Rikkunshito can help relieve symptoms in patients with functional dyspepsia. The study also looks at how it may affect the digestive lining and overall gut function.

Functional Dyspepsia3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Pain Management in Hernia Surgery: TAP Block vs. Local Infiltration

We are studying whether a TAP block offers better pain relief than local infiltration for patients after laparoscopic inguinal hernia repair. We also want to see if it leads to less need for pain medication.

Inguinal Hernia1-2 yearsMonitoring phase (IV)Standard MedicinesInternal MedicineOrthopedics and Traumatology

Non-Small Cell Lung Cancer: BNT327 with Chemotherapy

We are studying the safety and effectiveness of BNT327, an investigational therapy, combined with chemotherapy for patients with non-small cell lung cancer. This trial compares it to standard treatments to see which works better.

Non-small cell lung cancer>2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Pulmonary Hypertension: Sotatercept Study

We are investigating the safety and effects of sotatercept in individuals with pulmonary hypertension due to heart failure. This study aims to understand how well the treatment works over time.

Pulmonary Hypertension>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

Niemann-Pick Type C and GM1/GM2 Gangliosidosis: Nizubaglustat Study

We are investigating how well nizubaglustat works and its safety for children with Niemann-Pick type C disease and GM1 or GM2 gangliosidosis. This study aims to see if it can improve movement and coordination compared to a placebo.

Niemann-Pick Type C Disease and GM1/GM2 Gangliosidoses1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesNeurologyPediatrics

Chronic Infection in Hip and Knee Implants: 68Ga PET/CT Study

We are investigating whether a new imaging technique can accurately diagnose chronic infections in artificial hip and knee joints. This study compares its effectiveness to other existing diagnostic methods.

Prosthetic Joint Infection>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyOtolaryngology

V540A Vaccine Study in Healthy Adults

We are testing the V540A vaccine to see how it works in healthy adults. This study aims to evaluate its safety and effectiveness.

Human Papilloma Virus Infection1-2 yearsSafety phase (I)Infectious DiseasesOncology

Triple-Negative Breast Cancer: Optimizing Pembrolizumab Use

We are studying whether observing patients after surgery is as effective as continuing pembrolizumab treatment for those who responded well to initial therapy. This trial also looks at safety, quality of life, and fertility impacts.

Early Triple-Negative Breast Cancer (TNBC)6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Antibiotics in Cerebrospinal Fluid: A Study in Children

We are examining how well antibiotics work in the cerebrospinal fluid of children with an external ventricular drain. This research aims to improve treatment for infections in these patients.

Patients with External Ventricular Drain>2 yearsSafety phase (I)No PlaceboStandard MedicinesInfectious DiseasesPediatrics

HIV Treatment: Comparing DOR/3TC and DTG/3TC

We are studying whether a new two-drug regimen can maintain viral suppression in people living with HIV who are currently stable on a three-drug treatment. This trial will also assess various health outcomes and side effects over time.

HIV Disease>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInfectious Diseases

Alcohol-Associated Hepatitis: Alpha-1 Antitrypsin Treatment

We are studying whether intravenous Alpha-1 Antitrypsin can reduce inflammation in patients with severe alcohol-associated hepatitis. The trial also looks at its safety and effects on liver health.

Alcohol-Associated Hepatitis3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHepatologyInternal Medicine

Heart Failure: CDR132L Treatment Study

We are comparing a new treatment, CDR132L, with a placebo for people with heart failure and left ventricular hypertrophy. The goal is to see if it improves heart function and structure better than standard care.

Heart Failure with Reduced Ejection Fraction6-12 monthsEfficacy phase (II)>20 visitsPartially RemoteCardiologyInternal Medicine

Vemurafenib for BRAF Positive Juvenile Histiocytosis

We are studying the safety and effectiveness of vemurafenib in children with BRAF mutation-resistant histiocytosis. This trial aims to find the best dosage and treatment duration for these young patients.

Histiocytic Cell Proliferation>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Chronic Low Back Pain: Antibiotic Treatment Study

We are studying whether a three-month course of amoxicillin can help people with chronic low back pain and specific MRI changes. This trial compares the antibiotic treatment to a placebo to see if it offers any benefits.

Non-Specific Low Back Pain1-2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesInfectious DiseasesOrthopedics and Traumatology

Atenativ for Congenital Antithrombin Deficiency During Surgery

We are studying how Atenativ may help patients with congenital antithrombin deficiency during surgical procedures or childbirth. The trial looks at its safety, effectiveness, and how the body processes the medication.

Congenital Antithrombin Deficiency>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesGynecology and ObstetricsHematologyInternal Medicine

Meningiomas: ALpelisib and Trametinib Combination

We are testing a combination of two medications for patients with progressive, treatment-resistant meningiomas. The goal is to see if this approach can improve outcomes for these patients.

Meningiomas>2 yearsSafety phase (I)NeurologyOncology

Oxybutynin for Boys with Posterior Urethral Valves

We are studying whether early treatment with oxybutynin improves bladder function in boys after surgery for posterior urethral valves. The trial also looks at the safety of the medication and its effects on urinary tract infections.

Urethral Posterior Valve>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPediatricsUrology

Acute Kidney Injury: Angiotensin Receptor Blocker Study

We are studying whether an angiotensin receptor blocker can improve heart and kidney health in patients recovering from acute kidney injury after ICU discharge. This trial will help us understand its effects on overall health and safety.

Acute Kidney Injury>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCardiologyInternal MedicineNephrology

Tarlatamab for Advanced Small-Cell Lung Cancer

We are studying a new treatment for patients with metastatic or locally advanced small-cell lung cancer and other neuroendocrine carcinomas. The goal is to see how well it works and to understand its safety.

Metastatic Small Cell Lung Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology